--- title: "U.S. stock market midday update: Minerva Neurosciences down 12.21%, trading volume increased, market sentiment fluctuations attract attention" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/280358860.md" description: "Minerva Neurosciences fell 12.21%; ImmunityBio fell 23.72%, with a transaction volume of USD 543 million; AbbVie had a transaction volume of USD 537 million; Gilead Sciences fell 0.14%, with a transaction volume of USD 428 million; Amgen rose 0.11%, with a market value of USD 188.7 billion" datetime: "2026-03-24T18:32:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280358860.md) - [en](https://longbridge.com/en/news/280358860.md) - [zh-HK](https://longbridge.com/zh-HK/news/280358860.md) --- > 支持的语言: [English](https://longbridge.com/en/news/280358860.md) | [繁體中文](https://longbridge.com/zh-HK/news/280358860.md) # U.S. stock market midday update: Minerva Neurosciences down 12.21%, trading volume increased, market sentiment fluctuations attract attention **U.S. Stock Market Midday Update** Minerva Neurosciences fell 12.21%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** ImmunityBio fell 23.72%. Based on recent key news: 1. On March 24, the U.S. FDA issued a warning letter to ImmunityBio, accusing its television advertisements and podcasts about Anktiva of being misleading and violating federal law. This news caused the stock price to drop by 20%. Source: Reuters 2. On March 24, ImmunityBio acknowledged receiving the FDA's warning letter and stated it would work with legal and regulatory teams to respond and resolve the issues within the specified timeframe. This move failed to alleviate market concerns, and the stock price continued to decline. Source: Reuters 3. On March 24, analyst Edward Tenthoff stated that despite facing regulatory issues, ImmunityBio is expected to comply with the requirements and has not changed its revenue forecast for Anktiva. However, market confidence was shaken, and the stock price fell. Source: Reuters The biotechnology industry faces regulatory risks, and market volatility has intensified. AbbVie saw increased trading volume. Based on recent key news: 1. On March 23, Xilio Therapeutics announced that its collaboration with AbbVie drove its quarterly revenue growth, with Xilio's stock price rising by 3.18%. This collaboration has heightened market attention on AbbVie, potentially having a positive impact on its stock price. 2. On March 23, shareholders including Mercy Investment Services submitted a proposal to AbbVie, requesting the board chair to be independent. This proposal may spark discussions about the company's governance structure, affecting investor confidence. 3. On March 24, AbbVie announced an expansion of its partnership with Major League Baseball to raise cancer awareness. This initiative demonstrates the company's commitment to social responsibility and may enhance its brand image. The trend of collaboration in the biotechnology industry is strengthening. Gilead Sciences fell 0.14%. Based on recent key news: 1. On March 23, Gilead Sciences announced the acquisition of Ouro Medicines for $1.675 billion to enhance its inflammation product line. This move aims to improve its competitiveness in the autoimmune disease field by introducing the OM336 drug. This news led to a brief increase in stock price. 2. On March 24, Gilead Sciences reached a strategic collaboration with Galapagos to jointly develop Ouro's product portfolio. Galapagos will bear part of the development costs and share future profits. This collaboration further solidifies Gilead's position in the immunotherapy market On March 25th, Gilead Sciences' stock price fell by 0.50% due to mixed market reactions to its recent acquisition activities. Although the acquisition of Ouro Medicines is seen as a strategic expansion, investors are cautious about its short-term financial impact. The immunotherapy market is growing rapidly and is highly competitive. **Stocks ranked among the top in industry market capitalization** Amgen rose by 0.11%. There has been no significant news recently; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Analysts maintain a hold rating. no\_news ### 相关股票 - [Minerva Neurosciences (NERV.US)](https://longbridge.com/zh-CN/quote/NERV.US.md) ## 相关资讯与研究 - [Sino Medical Sciences Tech plans to seek Hong Kong listing](https://longbridge.com/zh-CN/news/280993435.md) - [Stronger-Than-Expected Revenue And Insider Selling Might Change The Case For Investing In Ingersoll Rand (IR)](https://longbridge.com/zh-CN/news/281706989.md) - [Wave Life Sciences (WVE) Is Up 14.4% After Phase 1 Data On Long‑Acting Obesity Drug WVE‑007](https://longbridge.com/zh-CN/news/281712132.md) - [BNB price outlook: can Binance Coin hold $600 support?](https://longbridge.com/zh-CN/news/281046132.md) - [Alexandria Real Estate Equities, Inc. Named One of the Most Trustworthy Companies in America by Newsweek for Fourth Consecutive Year | ARE Stock News](https://longbridge.com/zh-CN/news/281569903.md)